LDN-193719 is primarily used in research settings as a selective antagonist of the aryl hydrocarbon receptor (AhR). It is employed to study the role of AhR signaling in various biological processes, including immune regulation, inflammation, and cancer development. Due to its ability to inhibit AhR activation without affecting related pathways, it serves as a valuable tool for dissecting the molecular mechanisms involved in toxin-induced responses and autoimmune diseases. Researchers also utilize LDN-193719 to explore potential therapeutic strategies in conditions where AhR overactivation contributes to pathology, such as in certain cancers and chronic inflammatory disorders. Its specificity makes it suitable for in vitro and in vivo studies aiming to modulate immune responses and understand cellular differentiation pathways.